BAVARIAN NORDIC A/S (BV3.DE) Fundamental Analysis & Valuation

FRA:BV3 • DK0015998017

Current stock price

26.54 EUR
+0.64 (+2.47%)
Last:

This BV3.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. BV3.DE Profitability Analysis

1.1 Basic Checks

  • In the past year BV3 was profitable.
  • In the past year BV3 had a positive cash flow from operations.
  • In multiple years BV3 reported negative net income over the last 5 years.
  • BV3 had a positive operating cash flow in 4 of the past 5 years.
BV3.DE Yearly Net Income VS EBIT VS OCF VS FCFBV3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B -2B

1.2 Ratios

  • The Return On Assets of BV3 (9.20%) is better than 84.81% of its industry peers.
  • BV3 has a better Return On Equity (10.69%) than 84.81% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 10.31%, BV3 belongs to the top of the industry, outperforming 86.08% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for BV3 is in line with the industry average of 11.35%.
  • The 3 year average ROIC (10.17%) for BV3 is below the current ROIC(10.31%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 9.2%
ROE 10.69%
ROIC 10.31%
ROA(3y)8.78%
ROA(5y)3.94%
ROE(3y)11.2%
ROE(5y)4.49%
ROIC(3y)10.17%
ROIC(5y)N/A
BV3.DE Yearly ROA, ROE, ROICBV3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • The Profit Margin of BV3 (22.03%) is better than 83.54% of its industry peers.
  • In the last couple of years the Profit Margin of BV3 has grown nicely.
  • BV3 has a better Operating Margin (28.89%) than 87.34% of its industry peers.
  • BV3's Operating Margin has improved in the last couple of years.
  • BV3 has a Gross Margin (48.83%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of BV3 has grown nicely.
Industry RankSector Rank
OM 28.89%
PM (TTM) 22.03%
GM 48.83%
OM growth 3YN/A
OM growth 5Y6.23%
PM growth 3YN/A
PM growth 5Y8.01%
GM growth 3Y-3.3%
GM growth 5Y6.08%
BV3.DE Yearly Profit, Operating, Gross MarginsBV3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BV3.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BV3 is still creating some value.
  • The number of shares outstanding for BV3 has been reduced compared to 1 year ago.
  • Compared to 5 years ago, BV3 has more shares outstanding
  • The debt/assets ratio for BV3 has been reduced compared to a year ago.
BV3.DE Yearly Shares OutstandingBV3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
BV3.DE Yearly Total Debt VS Total AssetsBV3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

2.2 Solvency

  • An Altman-Z score of 6.88 indicates that BV3 is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.88, BV3 is in the better half of the industry, outperforming 75.95% of the companies in the same industry.
  • BV3 has a debt to FCF ratio of 0.10. This is a very positive value and a sign of high solvency as it would only need 0.10 years to pay back of all of its debts.
  • The Debt to FCF ratio of BV3 (0.10) is better than 96.20% of its industry peers.
  • BV3 has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • BV3 has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. BV3 outperforms 84.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.1
Altman-Z 6.88
ROIC/WACC1.39
WACC7.42%
BV3.DE Yearly LT Debt VS Equity VS FCFBV3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

2.3 Liquidity

  • BV3 has a Current Ratio of 4.22. This indicates that BV3 is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 4.22, BV3 is doing good in the industry, outperforming 75.95% of the companies in the same industry.
  • BV3 has a Quick Ratio of 2.64. This indicates that BV3 is financially healthy and has no problem in meeting its short term obligations.
  • BV3 has a Quick ratio (2.64) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.22
Quick Ratio 2.64
BV3.DE Yearly Current Assets VS Current LiabilitesBV3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BV3.DE Growth Analysis

3.1 Past

  • BV3 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.76%.
  • Measured over the past years, BV3 shows a decrease in Earnings Per Share. The EPS has been decreasing by -6.62% on average per year.
  • BV3 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.23%.
  • Measured over the past years, BV3 shows a very strong growth in Revenue. The Revenue has been growing by 27.51% on average per year.
EPS 1Y (TTM)-45.76%
EPS 3YN/A
EPS 5Y-6.62%
EPS Q2Q%-112.93%
Revenue 1Y (TTM)9.23%
Revenue growth 3Y25.61%
Revenue growth 5Y27.51%
Sales Q2Q%-30.18%

3.2 Future

  • The Earnings Per Share is expected to grow by 21.63% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 1.98% on average over the next years.
EPS Next Y65.22%
EPS Next 2Y33.05%
EPS Next 3Y30.9%
EPS Next 5Y21.63%
Revenue Next Year-9.63%
Revenue Next 2Y-4.1%
Revenue Next 3Y-1.74%
Revenue Next 5Y1.98%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BV3.DE Yearly Revenue VS EstimatesBV3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
BV3.DE Yearly EPS VS EstimatesBV3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

7

4. BV3.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • BV3 is valuated quite expensively with a Price/Earnings ratio of 34.92.
  • Compared to the rest of the industry, the Price/Earnings ratio of BV3 indicates a somewhat cheap valuation: BV3 is cheaper than 78.48% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.78, BV3 is valued a bit more expensive.
  • A Price/Forward Earnings ratio of 21.13 indicates a rather expensive valuation of BV3.
  • Based on the Price/Forward Earnings ratio, BV3 is valued cheaply inside the industry as 86.08% of the companies are valued more expensively.
  • BV3's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.54.
Industry RankSector Rank
PE 34.92
Fwd PE 21.13
BV3.DE Price Earnings VS Forward Price EarningsBV3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BV3 indicates a rather cheap valuation: BV3 is cheaper than 97.47% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, BV3 is valued cheaply inside the industry as 98.73% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.53
EV/EBITDA 4.29
BV3.DE Per share dataBV3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • BV3's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of BV3 may justify a higher PE ratio.
  • BV3's earnings are expected to grow with 30.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.54
PEG (5Y)N/A
EPS Next 2Y33.05%
EPS Next 3Y30.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BV3.DE Dividend Analysis

5.1 Amount

  • BV3 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BV3.DE Fundamentals: All Metrics, Ratios and Statistics

BAVARIAN NORDIC A/S

FRA:BV3 (4/8/2026, 7:00:00 PM)

26.54

+0.64 (+2.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-13
Inst Owners30.09%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap2.10B
Revenue(TTM)6.24B
Net Income(TTM)1.38B
Analysts87.27
Price Target34.92 (31.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.08%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.74%
Valuation
Industry RankSector Rank
PE 34.92
Fwd PE 21.13
P/S 2.52
P/FCF 11.53
P/OCF 5.77
P/B 1.22
P/tB 2.27
EV/EBITDA 4.29
EPS(TTM)0.76
EY2.86%
EPS(NY)1.26
Fwd EY4.73%
FCF(TTM)2.3
FCFY8.67%
OCF(TTM)4.6
OCFY17.32%
SpS10.54
BVpS21.73
TBVpS11.67
PEG (NY)0.54
PEG (5Y)N/A
Graham Number19.28
Profitability
Industry RankSector Rank
ROA 9.2%
ROE 10.69%
ROCE 13.5%
ROIC 10.31%
ROICexc 13.74%
ROICexgc 33.9%
OM 28.89%
PM (TTM) 22.03%
GM 48.83%
FCFM 21.82%
ROA(3y)8.78%
ROA(5y)3.94%
ROE(3y)11.2%
ROE(5y)4.49%
ROIC(3y)10.17%
ROIC(5y)N/A
ROICexc(3y)12.69%
ROICexc(5y)N/A
ROICexgc(3y)35.82%
ROICexgc(5y)N/A
ROCE(3y)13.32%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-1.03%
ROICexc growth 3YN/A
ROICexc growth 5Y22.79%
OM growth 3YN/A
OM growth 5Y6.23%
PM growth 3YN/A
PM growth 5Y8.01%
GM growth 3Y-3.3%
GM growth 5Y6.08%
F-Score8
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.1
Debt/EBITDA 0.03
Cap/Depr 184.16%
Cap/Sales 21.77%
Interest Coverage 108.04
Cash Conversion 107.08%
Profit Quality 99.07%
Current Ratio 4.22
Quick Ratio 2.64
Altman-Z 6.88
F-Score8
WACC7.42%
ROIC/WACC1.39
Cap/Depr(3y)175.5%
Cap/Depr(5y)229.02%
Cap/Sales(3y)21.71%
Cap/Sales(5y)32.95%
Profit Quality(3y)45.07%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.76%
EPS 3YN/A
EPS 5Y-6.62%
EPS Q2Q%-112.93%
EPS Next Y65.22%
EPS Next 2Y33.05%
EPS Next 3Y30.9%
EPS Next 5Y21.63%
Revenue 1Y (TTM)9.23%
Revenue growth 3Y25.61%
Revenue growth 5Y27.51%
Sales Q2Q%-30.18%
Revenue Next Year-9.63%
Revenue Next 2Y-4.1%
Revenue Next 3Y-1.74%
Revenue Next 5Y1.98%
EBIT growth 1Y91.94%
EBIT growth 3YN/A
EBIT growth 5Y35.45%
EBIT Next Year8.78%
EBIT Next 3Y9.18%
EBIT Next 5Y9.86%
FCF growth 1Y419.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.6%
OCF growth 3Y131.27%
OCF growth 5Y36.62%

BAVARIAN NORDIC A/S / BV3.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BAVARIAN NORDIC A/S?

ChartMill assigns a fundamental rating of 7 / 10 to BV3.DE.


What is the valuation status of BAVARIAN NORDIC A/S (BV3.DE) stock?

ChartMill assigns a valuation rating of 7 / 10 to BAVARIAN NORDIC A/S (BV3.DE). This can be considered as Undervalued.


What is the profitability of BV3 stock?

BAVARIAN NORDIC A/S (BV3.DE) has a profitability rating of 8 / 10.


Can you provide the financial health for BV3 stock?

The financial health rating of BAVARIAN NORDIC A/S (BV3.DE) is 8 / 10.


What is the expected EPS growth for BAVARIAN NORDIC A/S (BV3.DE) stock?

The Earnings per Share (EPS) of BAVARIAN NORDIC A/S (BV3.DE) is expected to grow by 65.22% in the next year.